# 03_PRIMARY_EVIDENCE_PACKAGE.md

# Primary Evidence Package

---

# Identity

| Field | Value |
|---|---|
| Evidence Package ID | EP-PP-0186 |
| Population Package ID | PP-0186 |
| Title | FGFR2 Testing |
| Version | 1.0.0 |
| Status | Gold — Ready for Integration |
| Evidence Model | Guideline-grounded educational synthesis with explicit evidence limitation |
| Primary Disease Context | Gastric adenocarcinoma |
| Primary Clinical Context | Molecular characterization / treatment-decision context |

---

# Clinical Question

> **What is FGFR2 testing, what type of molecular information can it provide, and why can an FGFR2-related finding matter in gastric cancer?**

---

# Educational Intent

This evidence package supports a patient-facing explanation of FGFR2 testing while preserving a strict evidence boundary.

The package must allow the reader to understand:

1. what FGFR2 is at a basic level;
2. what FGFR2 testing means;
3. why the exact assay matters;
4. why gene-level findings, amplification, and protein expression should not be automatically equated;
5. how FGFR2 testing relates to broader biomarker testing;
6. how FGFR2 testing relates to NGS;
7. what positive, negative, and indeterminate findings mean conceptually;
8. why a positive finding does not independently prescribe treatment;
9. why the current project Source Files do not support a universal FGFR2-specific testing algorithm.

---

# Scope

## Included

- FGFR2 biomarker identity.
- FGFR2 testing concept.
- Molecular-feature distinctions.
- Gene alteration concept.
- Amplification/copy-number concept.
- Protein-expression concept.
- Assay-context dependence.
- Specimen/tumor-material concepts.
- Relationship with NGS.
- Relationship with broader biomarker testing.
- Conceptual result interpretation.
- Potential treatment relevance.
- Patient-facing explanation.
- Evidence limitations.
- Adjacent-package boundaries.

## Excluded

- Detailed FGFR2 biology.
- FGFR signaling.
- Detailed FGFR2b biology.
- FGFR2b IHC scoring.
- FGFR2 FISH criteria.
- FGFR2 amplification thresholds.
- Universal FGFR2 testing.
- Companion diagnostics.
- Repeat-testing algorithms.
- NGS methodology.
- Variant interpretation.
- Detailed liquid-biopsy methodology.
- Prognostic algorithms.
- Resistance monitoring.
- Targeted-therapy treatment.
- Drug-specific management.
- Individualized medical advice.

---

# Primary Evidence Source

## NCCN Clinical Practice Guidelines in Oncology — Gastric Cancer, Version 2.2026

### Directly supported framework

The supplied NCCN material states that pathologic review and biomarker testing are important in diagnosis, classification, and molecular characterization of gastric cancer.

It describes a biomarker-testing framework in which:

- IHC;
- ISH;
- targeted PCR;
- NGS

may be used for different molecular questions.

NCCN also states that validated NGS may be considered later in the clinical course when sufficient tumor tissue is available.

The source further recognizes blood-based ctDNA testing as a possible way to obtain genomic information in selected advanced/metastatic settings.

These statements support the general architecture of PP-0186.

---

# Critical FGFR2-Specific Evidence Gap

The supplied project Source Files do **not** provide enough direct FGFR2-specific evidence to establish:

- universal FGFR2 testing in gastric cancer;
- one preferred FGFR2 assay;
- FGFR2b IHC as the universal test;
- FGFR2 amplification as the universal definition of positivity;
- a numerical FGFR2 positivity threshold;
- a companion diagnostic requirement;
- a universal repeat-testing schedule;
- an FGFR2-specific treatment-selection algorithm.

This gap is intentionally preserved.

The package must not convert general biomarker-testing principles into unsupported FGFR2-specific recommendations.

---

# Supporting Source Context

## General NCCN Biomarker Framework

The supplied NCCN gastric-cancer material provides examples of biomarker-specific testing frameworks.

For example, the guideline explicitly defines testing approaches for HER2, MSI/MMR, PD-L1, and CLDN18.2.

These examples demonstrate that:

> **Biomarker name alone is not enough; the test method and the biological feature being measured must be defined.**

PP-0186 uses this principle conceptually without importing the testing criteria of other biomarkers into FGFR2.

---

# Evidence Hierarchy

| Level | Source | Role |
|---|---|---|
| Level I | NCCN Gastric Cancer v2.2026 | Primary guideline for general biomarker-testing architecture |
| Supporting | NCI educational materials | Patient-facing clinical context |
| Supporting | ACS educational materials | Patient-facing context |
| Supporting | ESMO-ASCO Global Curriculum 2023 | General oncology framework |
| Evidence Gap | No supplied FGFR2-specific algorithm | Prevents unsupported FGFR2-specific claims |

---

# Evidence Matrix

| Clinical Claim | Supporting Evidence | Status |
|---|---|---|
| Biomarker testing is important in gastric-cancer molecular characterization | NCCN Gastric Cancer v2.2026 | Supported |
| Different biomarkers may require different testing approaches | NCCN Gastric Cancer v2.2026 | Supported |
| IHC, ISH, targeted PCR and NGS are used within the broader biomarker-testing framework | NCCN Gastric Cancer v2.2026 | Supported |
| Validated NGS may be considered when sufficient tumor tissue is available | NCCN Gastric Cancer v2.2026 | Supported |
| ctDNA can provide genomic information in selected advanced/metastatic settings | NCCN Gastric Cancer v2.2026 | Supported |
| FGFR2 is a dedicated biomarker topic in the project architecture | PP Registry | Supported |
| FGFR2 testing is a biomarker-specific question | Project architecture + PP Registry | Supported |
| FGFR2 testing is not synonymous with NGS | Biomarker-testing architecture | Supported |
| Gene alteration, amplification, and protein expression are distinct molecular concepts | Molecular-testing conceptual framework | Supported |
| A positive biomarker result does not independently prescribe treatment | Guideline architecture + package boundary | Supported |
| A negative biomarker result does not exclude all other biomarkers | Molecular biomarker framework | Supported |
| The exact assay matters for interpreting a molecular result | Biomarker-testing framework | Supported |
| Universal FGFR2 testing is recommended for all gastric cancers | Current supplied source set | **Not established** |
| FGFR2b IHC is the universal FGFR2 test | Current supplied source set | **Not established** |
| FGFR2 amplification is the universal definition of FGFR2 positivity | Current supplied source set | **Not established** |
| A numerical FGFR2 positivity threshold exists in the current supplied source set | Current supplied source set | **Not established** |
| A universal FGFR2 repeat-testing schedule exists | Current supplied source set | **Not established** |
| A specific FGFR2-targeted treatment should follow a positive result | Current supplied source set / downstream ownership | **Not established** |

---

# Evidence Notes

## Note 1 — Why the source gap is important

A patient-facing biomarker package must not present an assay, cutoff, or treatment linkage as established unless the project Source Files support it.

This is particularly important for PP-0186 because the current supplied NCCN source provides a detailed framework for several gastric-cancer biomarkers but does not provide an equivalent FGFR2-specific testing table or threshold.

---

## Note 2 — General biomarker architecture

The current source supports the concept that gastric-cancer biomarker testing is not one single laboratory test.

Different biomarkers can require different methods.

Therefore PP-0186 should teach:

> **The test method determines what the reported FGFR2 result actually represents.**

---

## Note 3 — NGS relationship

The NCCN source supports NGS as a broader molecular-testing platform.

PP-0186 therefore may explain that an FGFR2-related genomic finding can potentially be identified within a broader genomic assay when the relevant feature is covered.

However, this is not equivalent to saying:

> NGS is the recommended FGFR2 test.

That claim is not established by the current source set.

---

## Note 4 — Specimen context

The NCCN source recognizes the importance of sufficient tumor tissue for NGS.

This supports a patient-facing explanation that the quality and amount of available tumor material can affect molecular testing.

It does not establish an FGFR2-specific minimum tissue requirement.

---

## Note 5 — Blood-based testing

The NCCN source recognizes selected use of blood-based ctDNA testing.

This supports only a conceptual statement that blood-based genomic testing may provide tumor molecular information in selected circumstances.

It does not establish an FGFR2-specific ctDNA workflow.

---

## Note 6 — Result interpretation

An FGFR2 result must be interpreted according to:

- assay;
- specimen;
- molecular feature assessed;
- laboratory terminology;
- clinical context.

This is a core patient-safety principle.

---

## Note 7 — Treatment relevance

The project architecture separates:

**biomarker testing**

from:

**biomarker-guided targeted therapy**

Therefore PP-0186 may explain that an FGFR2-related finding can be clinically relevant, but treatment selection is delegated to PP-0190 and PP-0208.

---

# Clinical Claims Summary

The following claims are sufficiently supported for Gold educational use:

1. FGFR2 is a molecular biomarker topic within the gastric-cancer project architecture.
2. FGFR2 testing is a biomarker-specific testing question.
3. Different molecular assays can measure different biological features.
4. FGFR2 testing should not automatically be equated with amplification testing.
5. FGFR2 testing should not automatically be equated with FGFR2b protein testing.
6. NGS is a broader testing platform and is not synonymous with FGFR2 testing.
7. The specimen and assay context matter when interpreting a molecular result.
8. A positive FGFR2-related result does not independently prescribe treatment.
9. A negative FGFR2 result does not exclude other molecular biomarkers.
10. An indeterminate result may reflect limitations of the specimen or testing process.
11. The current project Source Files do not establish a universal FGFR2-specific testing algorithm or positivity threshold.
12. Detailed NGS methodology belongs to PP-0187.
13. Detailed genomic-report interpretation belongs to PP-0189.
14. Biomarker-guided targeted-therapy decisions belong to PP-0190 and PP-0208.

---

# Evidence Consistency Review

## Guideline Consistency

**PASS**

The package does not attribute an FGFR2-specific recommendation to NCCN that the supplied NCCN material does not contain.

---

## Internal Consistency

**PASS**

The package consistently distinguishes:

- FGFR2 from FGFR2 amplification;
- FGFR2 from FGFR2b protein testing;
- FGFR2 testing from NGS;
- biomarker testing from treatment selection;
- molecular biomarker from molecular classification.

---

## Evidence-to-Claim Consistency

**PASS**

Unsupported FGFR2-specific details are explicitly identified as evidence gaps rather than silently supplied from general knowledge.

---

## Architecture Consistency

**PASS**

PP-0186 is retained as a biomarker-specific package and is not merged with:

- PP-0187 NGS Biomarker Testing;
- PP-0189 Genomic Test Results;
- PP-0190 Biomarker Testing for Targeted Therapy;
- PP-0208 Targeted Therapy in Gastric Cancer.

---

# Evidence Gaps

1. No supplied FGFR2-specific universal gastric-cancer testing recommendation.
2. No supplied FGFR2-specific preferred assay.
3. No supplied FGFR2-specific positivity threshold.
4. No supplied FGFR2b-specific testing criterion.
5. No supplied FGFR2 amplification threshold.
6. No supplied FGFR2-specific companion-diagnostic framework.
7. No supplied FGFR2-specific repeat-testing schedule.
8. No supplied FGFR2-specific resistance-monitoring algorithm.
9. No supplied FGFR2-specific prognostic algorithm.
10. No supplied FGFR2-specific treatment-selection algorithm.

These gaps are **not** reasons to reject the PP architecture.

They are reasons to preserve an evidence-limited scope.

---

# Out-of-Scope Topics / Delegated Packages

| Topic | Delegated To |
|---|---|
| Gastric Cancer Molecular Classification | PP-0180 |
| NGS Biomarker Testing | PP-0187 |
| Molecular Subtypes | PP-0188 |
| Genomic Report Interpretation | PP-0189 |
| Biomarker Testing for Targeted Therapy | PP-0190 |
| Targeted Therapy in Gastric Cancer | PP-0208 |
| HER2 Testing | PP-0181 |
| MSI/MMR Testing | PP-0182 |
| PD-L1 Testing | PP-0183 |
| CLDN18.2 Testing | PP-0184 |
| TMB Testing | PP-0185 |

---

# Boundary Verification

**Core:** FGFR2-specific testing concept, molecular-feature distinctions, conceptual result interpretation, assay-context dependence, specimen/tumor-material concepts, relationship to broader biomarker testing and NGS, potential clinical relevance, and explicit evidence limitations.

**Supporting:** Basic FGFR2 molecular context, gene alteration/amplification/protein-expression distinctions, selected blood-based genomic-testing context, and relationship to other gastric-cancer biomarkers.

**Explicitly Excluded:** Detailed FGFR2 biology/signaling, exact IHC/FISH/NGS criteria, numerical thresholds, universal testing recommendations, companion-diagnostic rules, detailed NGS methodology, variant interpretation, detailed liquid-biopsy methodology, repeat-testing schedules, resistance/prognostic algorithms, and individualized targeted-therapy decisions.

**Delegated-to PP:** PP-0180, PP-0187, PP-0188, PP-0189, PP-0190, PP-0208 and relevant adjacent biomarker packages PP-0181–PP-0185.

---

# Future Update Triggers

Review the Evidence Package when:

- NCCN adds FGFR2-specific testing guidance.
- A validated FGFR2 assay is incorporated into a major guideline.
- A consensus positivity threshold becomes established.
- A companion diagnostic is approved or guideline-recognized.
- A gastric-cancer FGFR2-specific clinical trial materially changes treatment relevance.
- New evidence establishes an FGFR2-specific testing strategy.
- NGS reporting standards change materially.
- Adjacent package boundaries change.

---

# Evidence Package Decision

**APPROVED — GOLD**

The evidence package is sufficient for the approved PP-0186 educational scope.

The documented FGFR2-specific evidence gap is not an architecture blocker and is explicitly preserved.

---

# Source Traceability

| Source | Use |
|---|---|
| NCCN Gastric Cancer Version 2.2026 | Primary biomarker-testing framework |
| PP Registry | PP identity and adjacent architecture |
| CORE_WORKING_RULES v1.6 | Source-first, boundary, and production governance |
| FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0 | Artifact structure and QA architecture |
| PP Discussion depth and format example | Discussion/depth continuity reference |
| NCI / ACS / ESMO-ASCO supplied materials | Supporting patient-facing/general oncology context |

---

# Final Evidence Status

**PASS — GOLD — READY FOR INTEGRATION**
